Moleculin Biotech (NASDAQ:MBRX) Cut to Hold at Maxim Group

Maxim Group lowered shares of Moleculin Biotech (NASDAQ:MBRX) from a buy rating to a hold rating in a research report released on Wednesday, Marketbeat Ratings reports.

Separately, StockNews.com began coverage on shares of Moleculin Biotech in a report on Sunday, February 9th. They set a “sell” rating on the stock.

Moleculin Biotech Trading Up 71.7 %

Moleculin Biotech stock opened at $2.18 on Wednesday. The stock has a 50-day moving average price of $1.69 and a two-hundred day moving average price of $2.24. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.